<table>
<thead>
<tr>
<th></th>
<th>Supervised as</th>
<th>Years</th>
<th>Award</th>
<th>Position/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.</td>
<td>Louisa Grandin Sylvia, Ph.D.</td>
<td>7 yrs</td>
<td>K23 Award</td>
<td>Associate Director, MGH Bipolar Program; Instructor, HMS</td>
</tr>
<tr>
<td>20.</td>
<td>Jaqueline Ogutha, BA</td>
<td>2 yrs</td>
<td>Co-authored 2 abstracts</td>
<td>Medical student at University of Chicago Medical School</td>
</tr>
<tr>
<td>21.</td>
<td>Lisa Uebelacker, PhD</td>
<td>2 yrs</td>
<td>Co-authored 5 papers</td>
<td>Assistant Professor of Psychology at Brown University</td>
</tr>
<tr>
<td>22.</td>
<td>Brent Foster, MD</td>
<td>5 yrs</td>
<td>K23 Award</td>
<td>Instructor in Psychiatry. HMS, Director Mood Disorders Division, Geriatric Psychiatry Research Program, McLean Hospital</td>
</tr>
<tr>
<td>23.</td>
<td>Brian Brennan, MD</td>
<td>5 yrs</td>
<td>K23 Award</td>
<td>Schizophrenia and Bipolar Program, McLean Hospital, Instructor in Psychiatry, HMS</td>
</tr>
</tbody>
</table>

**Bibliography:**

**Original Reports:**


83. Montoya A, Weiss AP, Ruiz-Lopez I, Price BH, Nierenberg, AA. El tratamiento de la depresion despues de la respuesta inicial a la terapia electroconvulsiva (Depression Nierenberg revised 8/22/2011


122. Papakostas GI, Peterson T, Mahal Y, Misichoulon D, **Nierenberg AA**, Fava M. Quality of life in major depressive disorder: A review of the literature. General Hospital Psychiatry (accepted for publication).


129. Perlis RH. Iosifescu DV. Alpert J. **Nierenberg AA**. Rosenbaum JF. Fava M. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics. 45(3):224-9, 2004


146. Petersen T, Papakostas GI, Mischoulon D, Mahal Y, Alpert JE, Fava M, Nierenberg AA: Quality of Life in Treatment-Resistant Depression. European Psychiatry (accepted for publication).

Disorder: Data from the First 500 STEP-BD Participants. Am J Psychiatry 161:2222-9, 2004


155. Iosifescu DV, Clementi-Craven N, Fragua R, Papakostas GI, Petersen T, Alpert JE, Nierenberg AA, Fava M. Cardiovascular risk factors may moderate pharmacological


Outcome for Bipolar Patients With and Without Anxiety Disorders: Data from the First 1000 Participants in the Systematic Treatment Enhancement Program. British J Psychiatry 2006;189, 20-25.


189. Ghaemi SN, Hsu D, Thase ME, Wisniewski SR, Nierenberg AA, Miyahara S, Sachs G, for the STEP-BD Investigators. Psychotropic drug prescription patters in bipolar disorder: Data from the first 500 STEP-BD participants (accepted for publication).


213. Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Wisniewski SR, Kogan JN, **Nierenberg AA**, Calabrese JR, Marangell LB, Gyulai L, Araga M, Gonzalez JM,


217. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK. A Detailed Examination of Cytokine Abnormalities in Major Depressive Disorder. European Neuropsychopharmacology (in press)


227.


citalopram: Results of the nimh star*d trial. Depression and Anxiety 2009;26:612-621.


Integrating statistical and clinical research elements in intervention-related grant applications: Summary from an nimh workshop. Academic Psychiatry 2009;33:221-228.


Reviews and Educationally Relevant Publications:

8. Nierenberg, AA. Treatment resistant depression. Currents in Affective Disorders (August 1995)
11. Nierenberg, AA. SSRIs and relapse or recurrence in depression. [response to letter to the editor]. Primary Psychiatry 5:22 (1998)
32. Nierenberg AA, Sonino N. From clinical observations to clinimetrics: A tribute to Alvan R. Feinstein, M.D. Psychother Psychosom 73:131-133;2004
36. Nierenberg AA. Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolarI depression compared to lamotrigine. Evid Based Ment Health. 2007 Feb;10(1):12


**Editorials:**


2. **Nierenberg AA.** Distress: To treat or not to treat. *CNS Spectrums.* 2009:14(7):344-345


**Chapters:**


**Books:**


**Non-Print Materials:**


Abstracts:


17. Nierenberg, AA. Can we predict what initial treatment to select and when to change treatment. 22nd CINP Congress, Brussels, Belgium (2000).


**Book Reviews and Letters:**


**Letters:**


4. **Nierenberg, AA.** Early non-response to fluoxetine as a predictor of poor eight week outcome: rejoinder. Am J Psychiatry: (accepted for publication)

